Cadila Pharmaceuticals on Monday announced the launch of the Cadiflu Tetra Vaccine which is an advanced Quadrivalent Influenza Vaccine to prevent influenza, a recurrent, widespread, and debilitating viral infection. The vaccine is approved by DCGI for use in adults and children.
According to the company’s statement, Cadiflu Tetra Vaccine targets four strains of the Influenza virus subtype–A and B, responsible for seasonal epidemics. Developed using cutting-edge proprietary technology employing Nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material.
“The vaccine carries hemagglutinin (HA), neuraminidase (NA) and matrix1 (M1) proteins from the respective strains aggregated together in a single formulation. The VLP vaccine replicates the external structure of the viruses but does not contain any live genetic substance, which can cause viral replication and infection. Therefore, this vaccine is qualitatively superior and has a better safety profile,” the company said in a statement.
